Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RORC | P51449 | 9/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7828272 | 0.90 | L3MBTL1 (0.62) | L3MBTL1MEN1KMT2AHPGDHTT | |
| SCHEMBL24279586 | 0.90 | MEN1 (0.60) | L3MBTL1MEN1KMT2AHPGDHTT | |
| SCHEMBL1631811 | 0.87 | KEAP1 (0.66) | L3MBTL1RORCKEAP1NFE2L2 | |
| SCHEMBL121206 | 0.86 | RORC (0.70) | HPGDHTTRORCALDH1A1 | |
| SCHEMBL120825 | 0.85 | HPGD (0.61) | L3MBTL1MEN1KMT2AHPGDHTT | |
| SCHEMBL27849029 | 0.85 | HPGD (0.72) | L3MBTL1MEN1KMT2AHPGDHTT | |
| SCHEMBL119929 | 0.84 | RORC (0.79) | MEN1KMT2AHPGDHTTRORC | |
| SCHEMBL120536 | 0.83 | HTT (0.75) | L3MBTL1MEN1KMT2AHPGDHTT | |
| SCHEMBL30458040 | 0.82 | RORC (0.68) | MEN1KMT2AHTTRORCALDH1A1 | |
| SCHEMBL702692 | 0.81 | KEAP1 (0.68) | L3MBTL1KEAP1NFE2L2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102427810-A | Sulfamoylbenzoic acid derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC | 2012-04-25 | — | — | CN | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2424517-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc (JP) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM5, TRPM6 | L3MBTL1 4792/4885MEN1 1593/4885KMT2A 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.